Livestream

Treatment Crossover following Third-Line Therapy for Overactive Bladder, 2013-2019

Thursday, October 5, 2023

2:45 PM – 2:49 PM US PST

Location: Oregon Ballroom

Click to View Image
Image Label: Figure 1: Study Population

Presenting Author(s)

Preston Edge, MD

Fellow
Johns Hopkins / Greater Baltimore Medical Center
Baltimore, Maryland, United States

PDF

Co-Author(s)

LY

Lisa Yanek, M.P.H.

Assistant Professor
Johns Hopkins School of Medicine
Baltimore, Maryland, United States
DP

Danielle Patterson, MD S.M.

Assistant Professor
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
VH

Victoria L. Handa, MD M.H.S.

Professor
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States

Disclosure(s):

Preston Edge, MD: No financial relationships to disclose

Lisa Yanek, M.P.H.: No financial relationships to disclose

Danielle Patterson, MD S.M.: No financial relationships to disclose

Victoria L. Handa, MD M.H.S.: No financial relationships to disclose

Little is known regarding management of overactive bladder (OAB) after a trial of third line therapy (SNM, BTX or PTNS), and the AUA/SUFU guidelines do not make recommendations for optimal treatment progression. Our study investigated patterns of third line therapy crossover defined as use of an alternative procedural treatment after initial third line therapy for non-neurogenic OAB using an insurance claims database. The proportion of patients utilizing OAB medications after each third line therapy was also assessed.